CANbridge Pharmaceuticals Inc.
HKEX:1228.HK
0.22 (HKD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | CANbridge Pharmaceuticals Inc. |
Symbool | 1228.HK |
Munteenheid | HKD |
Prijs | 0.219 |
Beurswaarde | 93,039,592 |
Dividendpercentage | 0% |
52-weken bereik | 0.187 - 1.39 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. James Qun Xue M.B.A., Ph.D. |
Website | https://www.canbridgepharma.com |
An error occurred while fetching data.
Over CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)